

**DH 2025 Outpatient - All sources other than urine
(MHMH, APD, NLH, Southern Clinics)**



To obtain a sound statistical estimate of cumulative %S rates, organisms are included only when there are 30 or more unique patient isolates tested. Unless otherwise noted, data represents calendar year 2025.

| Number of Isolates | Ampicillin | Ox/Nafcillin | Ampicillin/Sulbactam | Piperacillin/Tazo | Cefazolin (first) | Ceftazidime (third) | Ceftriaxone (third) | Cefepime (fourth) | Meropenem | Linezolid | Gentamicin | Tobramycin | Vancomycin | Clindamycin | Tetracycline | Trimethoprim-sulfa | Ciprofloxacin | Levofloxacin | Minocycline |
|--------------------|------------|--------------|----------------------|-------------------|-------------------|---------------------|---------------------|-------------------|-----------|-----------|------------|------------|------------|-------------|--------------|--------------------|---------------|--------------|-------------|
|--------------------|------------|--------------|----------------------|-------------------|-------------------|---------------------|---------------------|-------------------|-----------|-----------|------------|------------|------------|-------------|--------------|--------------------|---------------|--------------|-------------|

GRAM POSITIVES

| | | | | | | | | | | | | | | | | | | | |
|---|-------------|------------|--|--|------------|--|--|--|--|------------|-----------------------|--|------------|-----------|-----------|------------|--|--|--|
| <i>Staphylococcus aureus</i> - ALL¹ | 1105 | 81 | | | 81 | | | | | 100 | 99² | | 100 | 79 | 90 | 93 | | | |
| -<i>Staphylococcus aureus</i> - MSSA | 896 | 100 | | | 100 | | | | | 100 | 99² | | 100 | 80 | 91 | 96 | | | |
| -<i>Staphylococcus aureus</i> - MRSA | 209 | 0 | | | 0 | | | | | 100 | 98² | | 100 | 73 | 85 | 76 | | | |
| <i>Staphylococcus lugdunensis</i> | 101 | 86 | | | 86 | | | | | 100 | 99² | | 100 | 85 | 95 | 100 | | | |
| Coagulase-negative <i>Staphylococcus</i> | 44 | 73 | | | 73 | | | | | 100 | 84² | | 100 | 70 | 74 | 86 | | | |

GRAM NEGATIVES

| | | | | | | | | | | | | | | | | | | | | |
|--|-----------------------|-----------------------|--|----------------------|------------------------|----------------------|-----------|----------------------|------------------------|----------------------|------------|----------------------|----------------------|--|----------------------|-----------------------|-----------|-----------|-----------|-----------|
| <i>Haemophilus influenzae</i> | 87 | 70³ | | | | | | | | | | | | | | | | | | |
| <i>Escherichia coli</i> | 34 | 55 | | 74 | 96⁴ | 61 | | 91 | 96⁴ | | 94 | | | | | 79 | 73 | 73 | | |
| <i>Klebsiella pneumoniae</i> | 34⁵ | 0^I | | 79 | 91⁶ | | | 88 | 91⁶ | | 97 | | | | | 82 | | 85 | | |
| <i>Proteus mirabilis</i> | 41⁵ | | | 95 | 100⁶ | | | 98 | 100⁶ | | 100 | | | | 0^I | 90 | | 95 | | |
| <i>Pseudomonas aeruginosa</i> | 138 | 0^I | | 0^I | 91 | | 96 | 0^I | 94 | 97 | | 99 | | | 0^I | 0^I | 89 | 88 | | |
| <i>Serratia marcescens</i> | 74⁵ | 0^I | | 0^I | | 0^I | | 99 | 100⁶ | | | | | | | 99 | 90 | 92 | | |
| <i>Stenotrophomonas maltophilia</i> | 76⁵ | 0^I | | 0^I | 0^I | | | 0^I | | 0^I | | 0^I | 0^I | | | 0^{IS} | 89 | | 79 | 94 |

¹ MRSA rate = 19% of all *Staphylococcus aureus* isolates from DH outpatient (MHMH/APD/NLH/Southern Clinics) non-urine sources.

² Gentamicin should not be used for monotherapy for gram-positive bacteria.

³ Susceptibility to ampicillin is based on a negative beta-lactamase test result.

⁴ Percentage accounts for isolates that test S + SDD. Zero isolates tested SDD.

⁵ 2024 + 2025 data combined.

⁶ Percentage accounts for isolates that test S + SDD. Combined year data, unable to report percent of isolates tested SDD.

^I Intrinsic resistance.

^{IS} *S. maltophilia* is intrinsically resistant to tetracycline, but not to doxycycline, minocycline or tigecycline.

For use by providers within the DH system only. Please do not share with pharmaceutical representatives.